FROM HOPE STUDY TO HOPE-2 AND HOPE-TOO STUDIES: DOES EXISTING PREVENTION STRATEGIES ARE NEED RADICAL IMPROVEMENT?


Cite item

Full Text

Abstract

The article discusses results of the HOPE-2 study, which have demonstrated ineffectiveness of folic acid, B6 and B12 vitamins in terms of reducing the risk of cardiovascular complications, and results of HOPE-TOO study, the results of which confirmed the need for the administration of ACE inhibitors, in particular, ramipril, in all patients with high risk of cardiovascular complications. Use of vitamin E in them, on the contrary, it is inappropriate and can be dangerous.

References

  1. Olds T.S., Tomkinson G.R., Ferrar K.E., et al. Trends in the prevalence of childhood overweight and obesity in Australia between 1985 and 2008. Int J Obes (Lond) 2009. [Epub ahead of print].
  2. Rosenson R.S., Reasner C.A. Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes. Curr. Opin. Cardiol. 2004;19:480-87.
  3. Чазова И.Е., Мычка В.Б. Метаболический синдром. М., 2004.
  4. Athyros VG, Ganotakis ES, Elisaf MS, et al. GREECE-METS Collaborative Group. Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol 2007;117(2):204-10.
  5. Шальнова С.А., Оганов Р.Г., Деев А.Д. и др. Здоровье российских врачей. Клинико-эпидемиологический анализ // Кардиоваскулярная терапия и профилактика. 2008;7(6):28-32.
  6. Бойцов С.А. Изучение патогенеза гипертонической болезни продолжается // Тер. арх. 2005;9:5-12.
  7. Brown B., Hall A. Renin-angiotensin system: the weight of evidence. Am. J. Hypertens. 2005;18:127S-133S.
  8. The Heart Outcomes Prevention Evaluation Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 2000;342:145-53.
  9. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-59.
  10. Clarke M.W., Burnett J.R., Croft K.D. Vitamin E in human health and disease. Crit. Rev. Clin. Lab. Sci. 2008;45(5):417-450.
  11. Yusuf S., Dagenais G., Pogue J. et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000;342(3):154-160.
  12. Lonn E., Yusuf S., Hoogwerf B. et al. HOPE Study; MICRO-HOPE Study. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care. 2002;25(11):1919-27.
  13. Mann J.F., Lonn E.M., Yi Q. et al. HOPE Investigators. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study.Kidney Int. 2004;65(4):1375-80.
  14. Lonn E., Yusuf S., Dzavik V. et al. SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001;103(7):919-25.
  15. Zanchetti A., Crepaldi G., Bond M.G., et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS - a randomized double-blind trial. Stroke 2004;35:2807-12.
  16. Herrmann W., Herrmann M., Obeid R. Hyperhomocysteinaemia: a critical review of old and new aspects. Curr. Drug. Metab. 2007;8(1):17-31.
  17. Antoniades C., Antonopoulos A.S., Tousoulis D. et al. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur. Heart J. 2009;30(1):6-15
  18. Yi F., Li P.L. Mechanisms of homocysteine-induced glomerular injury and sclerosis. Am. J. Nephrol. 2008;28(2):254-64.
  19. Den Heijer M., Lewington S., Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J. Thromb. Haemost. 2005;3(2):292-99.
  20. Fort J. Chronic renal failure: a cardiovascular risk factor. Kidney Int. 2005;99(Suppl.):S25-S29.
  21. Lonn E., Held C., Arnold J.M. et al. HOPE-2 Investigators. Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial. Can. J. Cardiol. 2006;22(1):47-53.
  22. Lonn E., Yusuf S., Arnold M.J. et al. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N. Engl. J. Med. 2006;354(15):1567-77.
  23. Mann J.F.E., Sheridan P., McQueen M.J. et al. Homocysteine lowering with folic acid and B vitamins in patients with chronic kidney disease - results of the renal Hope-2 study. Nephrol. Dial. Transplant. 2008;23:645-53.
  24. HOPE/HOPE-TOO Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes. Results of HOPE Study Extension. Circulation. 2005;112:1339-46.
  25. Lonn E., Bosch J., Yusuf S. et al. HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005;293(11):1338-47.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies